Clinical trials: Aggressive
Obstructive Coronary Artery Disease, Coronary Artery Disease
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well known that the reduction of cholesterol levels by statin therapy is associated with significant decreases in plaque burden.
- Trial name
- NCT01837823
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Skin Cancer
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
The goal of this clinical research study is to learn if Tarceva ® (erlotinib) when taken before and after radiation and/or surgery can help to control aggressive cutaneous squamous cell carcinoma.
- Trial name
- NCT01059305
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Adolescent, Bullying
Online Bullying Bystander Intervention for Middle Schools Phase II
School interventions to reduce bullying can be effective but also require substantial time and resources. Online technologies have the potential to deliver effective bullying interventions to a large number of middle school…
- Conditions
- Adolescent, Bullying, Technology, Mental Health
- Trial name
- STACII (NCT05572398)
- Testing
- STAC-T
- Where
- 2 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Background: The paradigm of combining therapeutic agents with non-overlapping toxicities for the treatment of malignancy produces clinical remissions and cures in a number of tumor types.
- Trial name
- NCT00069238
- Testing
- Alemtuzumab (Campath), EPOCH
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Personality Disorder
Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder
This study examines the effects of 12 months of dialectical behavior therapy (DBT) for subjects with borderline personality disorder on aggression, anger and emotional dysregulation.
- Trial name
- NCT00467038
- Testing
- Dialectical Behavior
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Thyroid Cancer
Nivolumab Plus Ipilimumab in Thyroid Cancer
This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for thyroid cancer.
- Trial name
- NCT03246958
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Dana-Farber Cancer Institute
Schizophrenia, Impulsive Behavior
Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally…
- Trial name
- NCT03838484
- Testing
- Nicotine Patch, 7 Mg/24 Hr
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Bullying
BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth
Given the limited impact of existing school-based interventions and the time associated with implementing them during school time, more efficient and effective intervention methods are needed.
- Trial name
- NCT06017050
- Testing
- BullyDown, Attention-matched control
- Where
- 2 sites in United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Center for Innovative Public Health Research
Malaria, Seizures
Aggressive Antipyretics for Fever Reduction in CNS Malaria
The study will examine whether prophylactic and scheduled treatment with acetaminophen and ibuprofen can decrease the maximum temperature experienced during the acute illness in children with CNS malaria.
- Conditions
- Malaria, Seizures, Coma, Parasitemia
- Trial name
- NCT03399318
- Testing
- Acetaminophen, Ibuprofen
- Where
- 3 sites in Malawi, Zambia
- Volunteers
- 256 people
- Sponsor
- University of Rochester
Sexual Behavior, Alcohol Drinking
Men's Sexual Risk Behaviors: Alcohol, Sexual Aggression, and Emotional Factors
Although correct, consistent condom use can greatly reduce sexually transmitted infections and unplanned pregnancies, resistance of condom use is common among young adults.
- Conditions
- Sexual Behavior, Alcohol Drinking, Sexual Aggression, Emotions
- Trial name
- NCT03900650
- Testing
- High provocation manipulation, Low provocation manipulation, Alcoholic beverage
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Arizona State University
Non-Hodgkin's Lymphoma
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
The current standard treatment for non-Hodgkin's lymphoma involves drugs called cyclophosphamide, doxorubicin, vincristine, prednisone and rituxan in a regimen called "R-CHOP." Using R-CHOP therapy, complete disappearance of…
- Trial name
- NCT00184002
- Testing
- Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Southern California
Heart Failure
Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure
Heart failure (HF) is the leading cause of hospitalization among Americans over the age of 65 years, affecting greater than 5 million in the U.S. alone.
- Trial name
- SACAR (NCT00588692)
- Testing
- SphygmoCor
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Myelodysplastic Syndromes
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00503880
- Testing
- filgrastim, clofarabine, cytarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Aggression
An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years
In this study, the investigators propose to examine whether the combination of a universal, elementary school-based preventive intervention with an indicated preventive and treatment intervention would yield greater impact on…
- Trial name
- P2P+IY (NCT03132805)
- Testing
- PATHS to PAX, PATHS to PAX and the Incredible Years
- Where
- United States
- Volunteers
- 5,233 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma…
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT01397825
- Testing
- Alisertib (MLN8237), Rituximab, Vincristine
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Millennium Pharmaceuticals, Inc.